+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epigenetics in Cardiovascular Disease. Translational Epigenetics Volume 24

  • Book
  • March 2021
  • Elsevier Science and Technology
  • ID: 5180560

Epigenetics in Cardiovascular Disease, a new volume in the Translational Epigenetics series, offers a comprehensive overview of the epigenetics mechanisms governing cardiovascular disease development, as well as instructions in research methods and guidance in pursing new studies. More than thirty international experts provide an (i) overview of the epigenetics mechanisms and their contribution to cardiovascular disease development, (i) high-throughput methods for RNA profiling including single-cell RNA-seq, (iii) the role of nucleic acid methylation in cardiovascular disease development, (iv) epigenetic actors as biomarkers and drug targets, (v) and the potential of epigenetics to advance personalized medicine. Here, readers will discover strategies to combat research challenges, improve quality of their epigenetic research and reproducibility of their findings. Additionally, discussion of assay and drug development for personalized healthcare pave the way for a new era of understanding in cardiovascular disease.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Preface SECTION I INTRODUCTORY INFORMATION CHAPTER 1 The ever-growing burden of cardiovascular disease CHAPTER 2 Epigenetics concepts: An overview CHAPTER 3 From classical signaling pathways to the nucleus

SECTION II EPIGENETICS MECHANISMS IN CARDIOVASCULAR DISEASE CHAPTER 4 DNA methylation in heart failure CHAPTER 5 Histone modifications in cardiovascular disease initiation and progression CHAPTER 6 RNA modifications in cardiovascular disease-An experimental and computational perspective CHAPTER 7 Regulatory RNAs in cardiovascular disease CHAPTER 8 Regulation of splicing in cardiovascular disease CHAPTER 9 Cardiac transcriptomic remodeling in metabolic syndrome CHAPTER 10 Sex differences in epigenetics mechanisms of cardiovascular disease CHAPTER 11 Epigenetics in cardiac development and human induced pluripotent stem cells

SECTION III BIOMARKER VALUE CHAPTER 12 Peripheral blood DNA and RNA biomarkers of cardiovascular disease in clinical practice CHAPTER 13 Epigenetics and physical exercise CHAPTER 14 Long noncoding RNAs and circular RNAs as heart failure biomarkers CHAPTER 15 Artificial intelligence in clinical decision-making for diagnosis of cardiovascular disease using epigenetics mechanisms

SECTION IV THERAPEUTIC POTENTIAL CHAPTER 16 Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease

SECTION V METHODOLOGICAL ISSUES CHAPTER 17 Single-cell RNA sequencing in cardiovascular science CHAPTER 18 Good laboratory and experimental practices for microRNA analysis in cardiovascular research CHAPTER 19 Analytical challenges in microRNA biomarker development: Best practices for analyzing microRNAs in cell-free biofluids CHAPTER 20 Concept of biological reference materials for RNA analysis in cardiovascular disease CHAPTER 21 Unbiased bioinformatics analysis of microRNA transcriptomics datasets and network theoretic target prediction Conclusions and Prespectives


Yvan Devaux Chair, EU-CardioRNA COST. Dr Devaux is Chairing the EU-CardioRNA COST Action, an international network of 30 European countries focusing on Transcriptomics in Cardiovascular Disease. Emma Louise Robinson School of Medicine, Division of Cardiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA.. Dr Robinson is leading a Working Group on Dissemination activities in the Action. The network, with 100+ individual experts in the field of Epigenetics in cardiovascular disease, constitutes an invaluable reservoir of co-authors for the Volume.